• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase 1 study of INCB086550, an oral PD-l1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Van Cutsem.pdf
    Size:
    973.4Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Van Cutsem, E.
    Prenen, H.
    Delafontaine, B.
    Spencer, K.
    Mitchell, T.
    Burris, H.
    Kotecki, N.
    Kristeleit, R.
    Pinato, D.
    Sahebjam, S.
    Graham, Donna
    Karasic, T.
    Daniel, J.
    O'Hayer, K.
    Geschwindt, R.
    Piha-Paul, S.
    Show allShow less
    Affiliation
    University of Leuven, Leuven, Belgium
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background INCB086550 is an orally administered small molecule that binds PD-L1 and inhibits PD-1/PD-L1 interaction. Translational data demonstrating markers of immune activation in patients following INCB086550 were previously reported.1 Preliminary clinical data from this phase 1 study are presented below. Methods Adult patients (≥18 years) with advanced solid tumors were enrolled into this open-label study. Patients had disease progression after standard available therapy or were intolerant of or ineligible for standard treatment. Measurable disease was required. A modified 3+3 dose-escalation design was employed, followed by dose expansions. The primary endpoints were safety and tolerability of INCB086550, identification of a pharmacologically active dose and/or MTD, and confirmation of the RP2D. Secondary endpoints included PK, pharmacodynamics, and efficacy as assessed by investigator-determined ORR and DCR (CR, PR, or SD ≥12 weeks). Results As of 9Apr2021, 79 patients received treatment (Table 1); 57.0% were female, 62.0% had ≥2 prior lines of therapy, and 16% received prior IO treatment. Forty-six (58.2%) patients had treatment-related TEAEs; those occurring in ≥5% of patients are presented in Table 2. Ten patients (12.7%) had grade ≥3 treatment-related TEAEs. Immune-related TEAEs occurred in 15 patients (19.0%); the most common (>1 patient) included peripheral sensory neuropathy (n=5), pruritus (n=3), immune-mediated neuropathy (n=2), and peripheral motor neuropathy (n=2). In total, 10 (12.7%) patients had TEAEs of peripheral neuropathy; all were grade ≤3. All grade 2 or 3 TEAEs of peripheral neuropathy resolved or improved with either study drug continuation without dose modification, dose reduction, or drug interruption/discontinuation. Patients with TEAEs leading to treatment interruption were 21 (26.6%), dose reduction 5 (6.3%), and discontinuation 13 (16.5%). Five patients (6.3%) died of a TEAE (cerebrovascular accident, dyspnea, general physical health deterioration, intestinal obstruction, intracranial hemorrhage [each n=1]); all fatal TEAEs were considered unrelated to study drug. The efficacy-evaluable population included 68 patients; ORR was 11.8% (95%CI, 5.2%–21.9%; CR, 1.5%; PR, 10.3%), and DCR was 19.1% (95%CI, 10.6%–30.5%; Table 3). Eight objective responses were observed at doses ≥400 mg BID (Table 4); 3 of these were noted among the 5 IO treatment-naive patients with MSI-H tumors who received 400 mg BID. Conclusions Immune-related AEs observed in this ongoing phase 1 study are consistent with those seen with antibody immune checkpoint inhibitors, with the exception of peripheral neuropathy. Preliminary efficacy of INCB086550 in tumor types known to be responsive to anti-PD-(L)1 therapy is encouraging and warrants further investigation.
    Citation
    Cutsem EV, Prenen H, Delafontaine B, Spencer K, Mitchell T, Burris H, et al. 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A559–60.
    Journal
    Journal for Immunotherapy of Cancer
    URI
    http://hdl.handle.net/10541/625247
    DOI
    10.1136/jitc-2021-SITC2021.529
    Additional Links
    https://dx.doi.org/10.1136/jitc-2021-SITC2021.529
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1136/jitc-2021-SITC2021.529
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.